SCHEMBL10312199

SCHEMBL10312199

C/C=C/c1cc(Nc2nc(/C=C/c3cccc(F)c3)nc(NCCCN3CCOCC3)n2)n[nH]1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 9/20 0.45
GSK3A P49840 2/20 0.43
GSK3B P49841 2/20 0.43
POLB P06746 1/20 0.43
GRK6 P43250 1/20 0.42
CSNK1D P48730 1/20 0.38
CSNK1E P49674 1/20 0.38
PIK3CA P42336 1/20 0.38
MTOR P42345 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
MELK Q14680 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
AURKA O14965 1/20 0.37
RAB9A P51151 2/20 0.37
KDM4E B2RXH2 1/20 0.37
GLA P06280 1/20 0.37
GAA P10253 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10312149 0.91 FLT3 (0.45) FLT3GSK3AGSK3BGRK6PIK3CA
SCHEMBL10312201 0.91 FLT3 (0.46) FLT3GSK3AGSK3BPOLBGRK6
SCHEMBL10312123 0.90 MELK (0.45) FLT3POLBGRK6MEN1KMT2A
SCHEMBL10312084 0.87 NTRK1 (0.46) FLT3GSK3AGSK3BPOLBGRK6
SCHEMBL10312200 0.86 GRK6 (0.35) FLT3GRK6CSNK1DCSNK1EMELK
SCHEMBL10312099 0.83 HRH4 (0.46) POLBPIK3CAMTORKMT2ARAB9A
SCHEMBL10312118 0.81 FLT3 (0.46) FLT3GSK3AGSK3BGRK6AURKA
SCHEMBL10312176 0.81 MELK (0.46) FLT3GSK3AGSK3BPOLBGRK6
SCHEMBL16556935 0.81 KDM4E (0.34) FLT3GSK3AGSK3BGRK6MEN1
SCHEMBL10312150 0.79 IGF1R (0.48) FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178758-A1 STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS CALIFORNIA CAPITAL EQUITY, LLC (US) 2012-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178758-A1 STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS STK25, STK35, SGK2 FLT3 152/4885GSK3A 315/4885GSK3B 297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.